Optimizing Care: Best Practices for Pharmacists in Administering Long-Acting Psychotropics

Ashley Maister, BS, PharmD, BCPP
Clinical Pharmacy Practitioner,
Mental Health
Corporal Michael J. Crescenz VA
Medical Center
Philadelphia, PA

Caitlin McCarthy, PharmD, BCPP
Clinical Associate Professor
Rutgers Ernest Mario School of Pharmacy
Clinical Pharmacist
Henry J. Austin Health Center
Piscataway, NJ

Patient Care Practice Management Community

aapp

Disclosures

- Drs. Maister and McCarthy do not have financial or other relationship with the manufacturer(s) of any commercial product(s) or provider(s) of any commercial service(s) discussed in this CE activity.

- This presentation will not include discussion of off-label, experimental, and /or investigational use of drugs or devices.

Note to attendees: *while presenters are encouraged to disclose any conflicts and to use the best evidence available, the presentations are not peer reviewed and attendees should accordingly verify details prior to making significant practice changes.*

aapp

Agenda

1. Presentation:
   - Benefits of long-acting injectable (LAI) psychotropics for patient care
   - Clinical practice guideline recommendations for use
   - Pharmacist administration of LAI psychotropics

2. Discussion: Current experiences with administering and/or managing LAI psychotropics in clinical practice

3. Activity: Administering LAI psychotropics

4. Debrief: Implementation into clinical practice

LAI Psychotropics

Available Products

Antipsychotics

Aripiprazole:
- Abilify Asimtufii®
- Abilify Maintena®
- Aristada® (+ Aristada Initio®)

Olanzapine:
- Zyprexa Relprevv®

Paliperidone:
- Erzofi®
- Invega Sustenna®
- Invega Trinza®
- Invega Hafyera®

Risperidone:
- Risperdal Consta®
- Rykindo®
- Uzedy®

Agents for Substance Use Disorders

Buprenorphine:
- Brixadi®
- Sublocade®

Naltrexone:
- Vivitrol®

Clinical Benefits of LAIs

Improved Adherence

Less Severe Symptoms

Reduced Relapse/Recurrence Risk

Lower Mortality Rates

Lower Healthcare Utilization

Lancet Psychiatry. 2021;8(5):387-404., *Schizophr Res.* 2018;197:274-280., *JAMA Netw Open.* 2022;5(7):e2224163., *CNS Drugs.* 2021;35(5):469-481.

Practice Guideline Support for LAIs

Practice Guideline	Recommendation(s)
American Psychiatric Association (APA) 2020 Schizophrenia Guidelines	*APA suggests* (2B) that patients receive treatment with a long-acting injectable antipsychotic medication if they prefer such treatment or if they have a history of poor or uncertain adherence
American Society of Addiction Medicine (ASAM) 2020 Opioid Use Disorder Focused Update	Extended-release injectable naltrexone is a recommended treatment for preventing relapse to opioid use disorder in patients who are no longer physically dependent on opioids, able to give informed consent, and have no contraindications for this treatment

aapp

Pharmacist Administration of LAI Psychotropics

Pharmacist Authority to Administer Long-Acting Injectable Antipsychotic Medications

Based on data collected by NASPA (updated May 2024)

Legend:
- Independent authority (e.g. direct authority, statewide protocol)
- Dependent authority (e.g. collaborative practice or physician order)
- Not authorized

https://naspa.us/blog/resource/med-admin-resources/

Clinical Outcomes

- Pharmacist administered LAI psychotropics has demonstrated:

Benefits	Opportunities for Growth
- Patient satisfaction and confidence - Medication adherence - Increased access to medication management	- Payment/reimbursement models - State laws for pharmacist-administered injections - Collaborative practice agreements - Scheduling and timing of appointments

Ment Health Clin. 2025;15(1): 17-24., *Am Pharm Assoc (2003)*. 2022;62: S29-34., *J Am Pharm Assoc (2003)*. 2018;58(4S): S24-29., *J Am Pharm Assoc (2003)*. 2017;57: e1-12.

Discussion: Current Experiences

Who is currently administering and/or managing LAI psychotropics in their practice?

Raise your hand!

aapp

For those who are currently administering and/or managing LAI psychotropic medications in their practice:

What is your practice setting?

aqpp

For those who are currently administering and/or managing LAI psychotropic medications in their practice:

What qualifications do pharmacists need to include this as part of their practice?

aapp

For those who are currently administering and/or managing LAI psychotropic medications in their practice:

How did you identify priority populations to receive their LAI psychotropic from a pharmacist?

For those who are currently administering and/or managing LAI psychotropic medications in their practice:

What outcomes are you tracking, how are you tracking them to demonstrate value to stakeholders, and how do you share this information?

For those who are currently administering and/or managing LAI psychotropic medications in their practice:

What have been key successes and challenges that you have encountered?

aapp

For those who are not currently administering and/or managing LAI psychotropic medications in their practice:

What questions do you have for the group that would help you feel better prepared to expand your practice and/or offer this service?

aapp

Activity: Administering LAI Psychotropics

Debrief: Implementation into Clinical Practice

aapp

Questions?

Thank you for attending!

aapp